Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) has received an average recommendation of “Hold” from the seven research firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $31.40.
PAHC has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price target on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th.
Read Our Latest Research Report on Phibro Animal Health
Phibro Animal Health Stock Performance
Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, equities analysts forecast that Phibro Animal Health will post 1.95 EPS for the current year.
Phibro Animal Health Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were issued a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s payout ratio is currently 28.92%.
Insider Transactions at Phibro Animal Health
In other news, CEO Jack Bendheim sold 38,303 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $45.29, for a total value of $1,734,742.87. Following the completion of the sale, the chief executive officer owned 20,577 shares in the company, valued at $931,932.33. This represents a 65.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 151,115 shares of company stock worth $6,557,541. 50.13% of the stock is owned by insiders.
Hedge Funds Weigh In On Phibro Animal Health
Hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC lifted its holdings in Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares during the period. Hughes Financial Services LLC purchased a new position in shares of Phibro Animal Health in the third quarter worth about $40,000. iSAM Funds UK Ltd purchased a new position in Phibro Animal Health in the 3rd quarter valued at approximately $61,000. Advisory Services Network LLC purchased a new position in shares of Phibro Animal Health in the third quarter valued at $96,000. Finally, EverSource Wealth Advisors LLC grew its holdings in Phibro Animal Health by 7,671.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after buying an additional 2,685 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.
About Phibro Animal Health
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
See Also
- Five stocks we like better than Phibro Animal Health
- Stock market legend warns: “An Ominous Day Is Coming for the Markets…”
- Another reason you need to own gold… [running out]
- Trump’s Final Shocking Act Begins February 24
- NEW: Gold makes history
- Deutsche Bank Just Raised Their Gold Target to $6,000
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
